News for ABT Stock

Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms Abbott Hosts Conference Call for First-Quarter Earnings Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD Abbott Declares 405th Consecutive Quarterly Dividend Abbott's 'Above the Bias' Film Reveals Misconceptions Can Impact Diabetes Care Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook PUBLIC HEALTH ADVOCACY INSTITUTE (PHAI) FILES CLASS ACTION AGAINST ABBOTT LABORATORIES OVER MARKETING OF "TODDLER MILK" Abbott Hosts Conference Call for Fourth-Quarter Earnings Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart Abbott Increases Quarterly Dividend for 53rd Consecutive Year University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis Tidepool Will Integrate With Abbott’s FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data CORRECTING and REPLACING Tidepool Will Integrate With Abbott’s FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data Seamless Data: Tidepool and Abbott’s New Cloud-to-Cloud Integration Partnership Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure Abbott and the Big Ten Conference Tackle U.S. Blood Shortages With First-of-Its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive' Helping People Recover From Devastating Hurricanes Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping Abbott and the Big Ten Conference Tackle U.S. Blood Shortages with First-of-its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive' Abbott Hosts Conference Call for Third-Quarter Earnings Abbott Declares 403rd Consecutive Quarterly Dividend Putting Health at the Center of Sustainability: Abbott Reports on Progress in Expanding Health Access, Broader 2030 Plan Performance Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S. Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores Abbott Scholars Ready To Join the Fight Against Diabetes What Happens When Communities Unite To Fight Diabetes? Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health Game On: Real Madrid Summer Tour Returns to U.S. Abbott and Partners Going Beyond Disaster Relief to Disaster Resilience Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance Abbott Hosts Conference Call for Second-Quarter Earnings Innovating for a Healthier, Sustainable Future Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health Abbott Declares 402nd Consecutive Quarterly Dividend Biowearables 101: Health Tech That Goes Deeper Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee It’s Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside Abbott Hosts Conference Call for First-Quarter Earnings Diabetes and Heart Disease: How to Manage Your Risk Abbott Extends Innovative Health Partnership With Real Madrid and the Real Madrid Foundation Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes Abbott Declares 401st Consecutive Quarterly Dividend FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve New Study Shows Mixed Reality Technology for Blood Donation From Abbott and Blood Centers of America Helps Ease Stress, Encourages People To Donate Again Decade of Impact: Transforming Care in Tanzania Abbott Launches New PROTALITY(TM) Brand To Support Adults on Their Weight Loss Journey Can a 'Food as Medicine' Approach Help Manage Diabetes? New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+ Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook Continuing to Lead the Way in Sustainability Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor Abbott Hosts Conference Call for Fourth-Quarter Earnings Abbott to Present at J.P. Morgan Healthcare Conference Abbott Increases Quarterly Dividend for 52nd Consecutive Year Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump Participants in Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV Abbott and Damar Hamlin Team Up To Build Heart Health Community With New Heartmates Program Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology Abbott and Damar Hamlin Team Up to Build Heart Health Community with New HeartMates Program Tackling Student Loans and Saving - Together Ninety-One Percent of Young Adults With Student Loans Say Financial Stress Is Impacting Their Wellness Ninety-One Percent of Young Adults With Student Loans Say Financial Stress is Impacting Their Wellness -- Abbott Launches Blueprint of Award-Winning Program to Help Companies Tackle This Problem Late-Breaking Data Show Esprit™ BTK Drug-Eluting Resorbable Scaffold Reduces Chronic Limb-Threatening Ischemia Progression Compared to the Standard of Care Can Health Tech Be the Most Helpful Technology of All? Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves Sharing the Access Code to Help Open Up Diabetes Care Abbott Recognized on Fortune Change the World List Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range Abbott Hosts Conference Call for Third-Quarter Earnings Abbott Shares Progress on Sustainability Performance, Including Company’s Priority of Innovating for Greater Health Access Abbott Completes Acquisition of Bigfoot Biomedical Abbott Declares 399th Consecutive Quarterly Dividend Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets Abbott and WeightWatchers Connected App Experience is Now Available for People Living with Diabetes Virus Hunt Zooms In To Focus on New Potential Pandemics One Size Does Not Fit All: The Future of Clinical Trials Less Is More: Abbott’s Approach to Packaging Innovation Abbott Joins Billion Dollar Roundtable Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business Shaping the Future of Abbott and Healthcare Abbott Receives FDA Approval for World's First Dual-Chamber Leadless Pacemaker Abbott Hosts Conference Call for Second-Quarter Earnings The American Diabetes Association and Abbott Collaborate on First-of-Its-Kind Therapeutic Nutrition Program for People With Diabetes Abbott's FreeStyle Libre® 2 Receives National Reimbursement in France for All People with Diabetes Who Use Insulin¹ Abbott Declares 398th Consecutive Quarterly Dividend Abbott and Real Madrid's Goal: Beating Malnutrition Abbott, Real Madrid and the Real Madrid Foundation Band Together To ‘Beat Malnutrition’ Globally Through New Campaign Abbott, Real Madrid and the Real Madrid Foundation Band Together to 'Beat Malnutrition' Globally Through New Campaign European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints Coming Together on the Journey to End Parkinson’s Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options Abbott Completes Acquisition of Cardiovascular Systems, Inc. Climate Change: The Impact on Viral Outbreaks Abbott's Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients Abbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries FDA Clears Reader for Abbott's FreeStyle Libre® 3 System Abbott Hosts Conference Call for First-Quarter Earnings Don’t Mess With Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get It Checked' In New Public Service Announcement Seeking Answers About Transgender Heart Health Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement Abbott: Clean, Accessible Water for a Healthy Future Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices Inspiring the Next Generation of STEM Pioneers Abbott Recognized as the Industry Leader in S&P Global’s Sustainability Yearbook for the 10th Year Abbott Declares 397th Consecutive Quarterly Dividend Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results Abbott to Acquire Cardiovascular Systems, Inc. The Virus Hunt: New Video Series Highlights Abbott Pandemic Defense Coalition The Partnerships Changing How You Manage Diabetes FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook Abbott, Blood Centers of America Launch First-of-Its-Kind Mixed Reality Experience for Use During Blood Donation Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis Ra Medical Systems Completes Merger with Catheter Precision Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation Abbott Hosts Conference Call for Fourth-Quarter Earnings Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany Abbott to Present at J.P. Morgan Healthcare Conference Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain Abbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology 24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022 Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life Abbott Hosts Conference Call for Third-Quarter Earnings Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies Abbott Declares 395th Consecutive Quarterly Dividend Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance Abbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression Abbott Hosts Conference Call for Second-Quarter Earnings Abbott Declares 394th Consecutive Quarterly Dividend Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor Diandra “Fu” Debrosse Zimmermann Becomes First Black Woman Ever Appointed to Lead a Multidistrict Litigation with Co-Lead Counsel Selection in Baby Formula MDL Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise Abbott to Release Metabolic Nutrition Formulas Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device New Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes Abbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App Abbott Reports First-Quarter 2022 Results Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms Abbott Hosts Conference Call for First-Quarter Earnings Abbott's FreeStyle® Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure Abbott Declares 393rd Consecutive Quarterly Dividend Abbott Voluntarily Recalls Powder Formulas Manufactured at One Plant Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms ACELYRIN Appoints Melanie Gloria as Chief Operating Officer Abbott Announces Future of Biowearables at Consumer Electronics Show Abbott Hosts Conference Call for Fourth-Quarter Earnings Abbott's Proclaim™ XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S. Abbott to Present at J.P. Morgan Healthcare Conference Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman Abbott Increases Quarterly Dividend for 50th Consecutive Year Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI) Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance Jason Sudeikis Joins Abbott, Real Madrid at New York Stock Exchange to Support Children's Health Abbott and Real Madrid Team Up to Support the Health and Nutrition of Children Globally Abbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions Abbott Hosts Conference Call for Third-Quarter Earnings Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease Abbott Declares 391st Consecutive Quarterly Dividend Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations Abbott Reports Second-Quarter 2021 Results Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients Late-Breaking Data Demonstrate Abbott's FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes Abbott Hosts Conference Call for Second-Quarter Earnings People Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit Abbott Declares 390th Consecutive Quarterly Dividend Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump Abbott Issues Updated 2021 Outlook Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial Abbott Reports First-Quarter 2021 Results Abbott Begins Shipping BinaxNOW™ COVID-19 Ag Self Test to Retailers Today World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use Abbott Hosts Conference Call for First-Quarter Earnings Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants Abbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S. Abbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure Abbott Declares 389th Consecutive Quarterly Dividend Consumer Health Trends are Fueling an Infant Nutrition Surge Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021 Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device Abbott to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant Abbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions Abbott Hosts Conference Call for Fourth-Quarter Earnings As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner Abbott to Present at J.P. Morgan Healthcare Conference FDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test Abbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health Abbott Increases Quarterly Dividend by 25% Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI) Abbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test Abbott Releases ID NOW™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation Abbott Hosts Conference Call for Third-Quarter Earnings Abbott Declares 387th Consecutive Quarterly Dividend Abbott Introduces Libre Sense Glucose Sport Biosensor in Europe, World's First Glucose Biosensor Designed for Athletes Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold Abbott's FreeStyle® Libre 2 iCGM System Now Available to Medicare Beneficiaries Abbott's Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month Abbott Hosts Conference Call for Second-Quarter Earnings New Late-Breaking Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes Using Insulin or Not Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences New Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart Therapies Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation Abbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations New Research Finds Abbott's Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery Blockages